Project description
A novel drug against multiple sclerosis
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterised by debilitating relapses associated with loss of neurological function. MS affects millions of individuals worldwide, but existing treatment options are primarily palliative. The EU-funded ENHANCIDO project aims to evaluate novel small molecules potentiating the activity of the immunosuppressive enzyme IDO1 known to reduce MS severity in animal models. By evaluating the efficacy, pharmacokinetics and pharmacodynamics of these compounds, scientists hope to deliver an innovative first-in-class drug that will improve the lives of MS patients. More importantly, this drug has the potential to be used to treat other autoimmune diseases.
Fields of science
Programme(s)
Funding Scheme
ERC-POC-LS - ERC Proof of Concept Lump Sum PilotHost institution
06123 Perugia
Italy
See on map
Beneficiaries (1)
06123 Perugia
See on map